Evotec SE (NASDAQ:EVO - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $4.35, but opened at $4.61. Evotec shares last traded at $4.66, with a volume of 4,974 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a "buy" rating and issued a $8.00 price objective on shares of Evotec in a report on Thursday, November 7th.
View Our Latest Stock Report on EVO
Evotec Price Performance
The stock's 50 day moving average price is $4.44 and its 200-day moving average price is $4.04. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43.
Institutional Investors Weigh In On Evotec
Institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP grew its holdings in Evotec by 29.7% in the 3rd quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company's stock worth $9,616,000 after acquiring an additional 602,858 shares during the last quarter. Mediolanum International Funds Ltd purchased a new stake in shares of Evotec during the third quarter worth about $512,000. Finally, Clear Harbor Asset Management LLC bought a new stake in shares of Evotec in the third quarter worth about $104,000. 5.81% of the stock is currently owned by hedge funds and other institutional investors.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Further Reading
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
